

Hand/Wrist Arthritis (CMC) and Regenxx-SD vs. -C Outcome

What's important here? The patient results detailed on this infographic are fairly evenly split between men and women who are roughly normal weight (BMI 25). These two groups have similar demographics.

	Regenxx-SD	Regenxx-C
N	55 patients	23 Patients
Male	25 (45%)	13 (56.5%)
Female	30 (55%)	10 (43.5%)
Age	57.3 (21-82)	59.0 (29-71)
BMI	24.0 (19.7-28.9)	25.4 (21.5-30.5)



Same day procedure that isolates a fraction of the bone marrow that's rich in stem cells.




Cultured stem cell procedure where bone marrow mesenchymal stem cells are isolated and then cultured to larger numbers over two weeks.

In a chart review, the majority of these patients had severe arthritis.

Same Day vs. Cultured

Caution! This is registry data, which is not the same as a drug company style controlled trial.
The Regenxx-C procedure is not approved by the U.S. FDA and is only performed by independent, licensed third party companies outside of the U.S.

Mean Likert Improvement



What does this mean?
Above is the mean improvement for the patients that responded to questionnaires when the last available report was used for that patient. These patients may have reported anything from 0% to 50% to 80% improvement and above is the average of all of those reports.

Details: Two patients were excluded from the -SD analysis because one had severe progressive hand OA at a young age (not common wear and tear osteoarthritis) and the second had a loose body in the CMC joint prior to the procedure that was deemed a surgical issue, but the patient opted for injection treatment. No patients were excluded from the -C data set. Patient n for the graph above for -SD was 20 and for -C n=16.